Rigosertib Sodium
Tier C — Watch / tradeRigosertib Sodium
Targets：CDK1, Class I PI3K, PLK1
Indications (approved)：Non-small cell lung cancer, Adenocarcinoma, 营养不良性大疱性表皮松解, Myelodysplastic syndrome, Chronic myelomonocytic leukaemia, Pancreatic cancer, Melanoma, 皮肤黑色素瘤
Regional status
Synthetic routes & intermediates2 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| RIGO-001 | 119-10-8 | 1-methoxy-4-methyl-2-nitrobenzene |
| RIGO-002 | 61010-34-2 | 4-(bromomethyl)-1-methoxy-2-nitrobenzene |
| RIGO-003 | 68-11-1 | 2-mercaptoacetic acid |
| RIGO-004 | 1267334-70-2 | 4-(4-methoxy-3-nitrophenyl)butanoic acid |
| RIGO-005 | 592542-51-3 | 2-((4-methoxy-3-nitrobenzyl)sulfonyl)acetic acid |
| RIGO-006 | 830-79-5 | 2,4,6-trimethoxybenzaldehyde |
| RIGO-007 | 592542-52-4 | (E)-1,3,5-trimethoxy-2-(2-((4-methoxy-3-nitrobenzyl)sulfonyl)vinyl)benzene |
| RIGO-008 | 1808657-87-5 | (E)-2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)aniline |
| RIGO-009 | 96-32-2Available | methyl 2-bromoacetate |
| RIGO-010 | 592542-61-5 | (E)-methyl 2-((2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)phenyl)amino)acetate |
| Code | CAS No. | Intermediate |
|---|---|---|
| RIGO-002 | 61010-34-2 | 4-(bromomethyl)-1-methoxy-2-nitrobenzene |
| RIGO-006 | 830-79-5 | 2,4,6-trimethoxybenzaldehyde |
| RIGO-008 | 1808657-87-5 | (E)-2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)aniline |
| RIGO-010 | 592542-61-5 | (E)-methyl 2-((2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)phenyl)amino)acetate |
| RIGO-011 | - | ((4-methoxy-3-nitrobenzyl)thio)methanediamine hydrobromide |
| RIGO-012 | 908344-21-8 | (4-methoxy-3-nitrophenyl)methanethiol |
| RIGO-013 | 136612-71-0 | 2-ethynyl-1,3,5-trimethoxybenzene |
| RIGO-014 | 1330633-86-7 | (E)-(4-methoxy-3-nitrobenzyl)(2,4,6-trimethoxystyryl)sulfane |
| RIGO-015 | 908344-08-1 | (E)-2-methoxy-5-(((2,4,6-trimethoxystyryl)thio)methyl)aniline |
| RIGO-016 | 1330633-87-8 | 2-(2,2-dibromovinyl)-1,3,5-trimethoxybenzene |
Frequently asked questions
What are the approved indications of Rigosertib Sodium?
Approved indications include: Non-small cell lung cancer, Adenocarcinoma, 营养不良性大疱性表皮松解, Myelodysplastic syndrome, Chronic myelomonocytic leukaemia, Pancreatic cancer, Melanoma, 皮肤黑色素瘤.
When does the Rigosertib Sodium patent expire?
No public expiry year is available for Rigosertib Sodium yet; this page updates once verified.
How many synthesis routes are recorded for Rigosertib Sodium?
2 synthesis routes are recorded; the shortest is 8 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Rigosertib Sodium intermediates?
1 intermediate CAS of Rigosertib Sodium are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Rigosertib Sodium intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21